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ABSTRACT (256 words) 
Aims. Corticosteroid-dependent,colchicine-resistant refractory recurrent pericarditis (RRP) 
is challenging since resistant to conventional treatment (NSAIDs, colchicine, and 
corticosteroids). Interleukin-1 blockade with anakinra may be beneficial in RRP according 
to case reports, small case series and a single RCT on 21 patients. This registry was 
aimed to evaluate anakinra efficacy and safety in a “real world” population. 
Methods and Results. This international multicenter registry enrolled 224 consecutive 
RRP patients (aged 46±14 years old, 63% females, 5.3±3.7 recurrences, 75% idiopathic 
etiology) with a mean disease duration of 27 months. Patients had C-reactive protein 
elevation in 91%, pericardial effusion in 88% of cases, and were treated with anakinra 
100mg/day sc for a median time of 6 months (IQR,3-12). Pericarditis recurrence rate was 
the primary endpoint. ED admissions, hospitalizations and adverse events (AE) were 
secondary endpoints. Anakinra reduced pericarditis recurrences (6-fold reduction, from 
2.33 to 0.39 flares-patient/year), ED admissions (11-fold reduction, from 1.08 to 0.10 
admissions-patient/year), hospitalizations (7-fold reduction, from 0.99 to 0.13 
hospitalizations-patient/year) and corticosteroids use (from 80% before anakinra to 27% 
after treatment).  
AE occurred in 44% patients, without severe AE, mostly transitory skin reaction at the 
injection site. Seven patients (3%) needed anakinra withdrawal because of AE. A full-dose 
treatment duration of at least 3 months followed by a tapering period of at least 3 months 
were the therapeutic schemes associated with a lower risk of recurrence. 
Conclusion. Anakinra is efficacious and safe in the long-term reduction of recurrences in 
RRP patients, furthermore decreasing ED admissions/hospitalizations and corticosteroids-
dependence. Anakinra efficacy may be further increased by proper treatment protocols. 
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INTRODUCTION 
Acute pericarditis is the most common form of pericardial disease, accounting for 
approximately 5% emergency department admissions for non-ischemic chest pain. 
Recurrent pericarditis affects up to 30% patients after a first episode, raising up to 50% in 
those who are not treated with colchicine and with multiple recurrences1,2. Possible 
treatments for the management of recurrences include non-steroidal anti-inflammatory 
drugs (NSAIDs), colchicine, corticosteroids, immunomodulatory agents and 
pericardiectomy3. Patients with inadequate clinical response to conventional medical 
therapy (NSAIDs, colchicine, corticosteroids) and multiple unsuccessful attempts of 
corticosteroids tapering may develop tenacious forms of corticosteroid-dependent and 
colchicine-resistant refractory recurrent pericarditis (RRP), resulting in severe impairment 
of their quality of life. These patients have a challenging clinical management because of 
refractory symptoms and high prevalence of side effects due to chronic treatment with 
corticosteroids4. 
Although the pathogenesis of idiopathic recurrent pericarditis has not been fully 
explained lacking suitable animal models, according to recent theories5,6 an amplified and 
self-sustained auto-inflammatory or auto-immune response following exogenous or 
endogenous triggers may explain incessant and recurrent pericarditis. Interleukin-1 
blockade with anakinra is of growing interest in this setting because it may have the 
potential to dramatically reduce pericarditis recurrences, although strong evidence-based 
data are lacking in literature7. Indeed, current knowledge about anakinra use in RRP 
patients is based on 14 case reports8–21, 4 case series on 10-14 patients22–25, one 
randomized and controlled trial on 21 patients26. The generalizability of such limited 
findings in a real-world clinical setting, involving different patient populations and single 
center practice is a key question. The IRAP international, all-comers, multicenter registry 
was designed to specifically investigate this question.  
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The aim of this registry was to verify and evaluate the long-term efficacy and safety of 
anakinra in the treatment of corticosteroid-dependent and colchicine-resistant recurrent 




The International Registry of Anakinra for Pericarditis (IRAP) is an international, all-
comers, multicenter observational cohort study involving 14 referral centers for pericardial 
diseases across 6 different countries (see appendix A). The present study complied with 
the Declaration of Helsinki and subsequent modifications. The study was approved by the 
Ethical Committees at each participating center. All patients provided written informed 
consent. All consecutive patients afferent for RRP at each clinical site between 2014 and 
2018 were enrolled at the time of a pericarditis recurrence if they were eligible to receive 
anakinra treatment according to local and international guidelines and were adult (>18 
years old). 
Inclusion and exclusion criteria 
All patients eligible for inclusion in the present registry had corticosteroid-dependent 
and colchicine-resistant refractory recurrent pericarditis (RRP), defined as a first episode 
of acute pericarditis followed by a minimum of 2 recurrences despite guideline-based 
traditional medical treatment (NSAIDs, colchicine, corticosteroids). Corticosteroid-
dependence was defined as the impossibility to withdraw steroids without incurring in a 
pericarditis recurrence. The first episode of pericarditis was diagnosed in the presence of 
at least 2 of the following criteria: pericarditic chest pain (sharp, pleuritic, improved by 
sitting up and leaning forward), friction rubs, ST-segment elevation or PR-segment 
depression on electrocardiogram, new or worsening pericardial effusion. A recurrence was 
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diagnosed when pericarditic chest pain reoccurred along with 1 or more of the following 
signs: fever, friction rubs, electrocardiographic changes, new or worsening pericardial 
effusion, CRP elevation.1,2,27. 
Exclusion criteria were specific contraindications to anakinra treatment: 
hypersensitivity to the active substance or to E. coli-derived proteins, neutropenia 
(absolute neutrophil count <1,5x109/L); active tubercular infection; active cancer. 
Study Protocol 
Enrolled patients received anakinra 100 mg once daily by subcutaneous (sc) injection. 
Concomitant medical treatment for pericarditis (NSAIDs, colchicine, corticosteroids) was 
maintained or tapered and suspended according to clinician choice based on patient 
evaluation. Clinical, laboratory testing, electrocardiographic and echocardiographic 
assessment were performed in all patients at the time of enrollment, according to local 
practice and following international guidelines. 
Study End-points 
The primary end-point was the variation of pericarditis recurrence rate after the 
initiation of anakinra treatment. The secondary end-points were: the variation of 
emergency department (ED) access rate and hospitalization rate after the after the 
initiation of anakinra treatment; the prevalence of patients on corticosteroid treatment after 
the initiation of anakinra treatment.  
The occurrence of any adverse event (AE) and AE-related drug discontinuation was 
recorded and assessed as a safety end-point. 
 
Statistical analysis 
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Blinded and independent analysis of data was performed by AA, GMDF, and EP in 
Turin (Coordinating Center). This cohort study followed the recommendations of the 
STROBE statement28. A minimum sample size of 24 patients was estimated to be 
sufficient to detect a difference in recurrence rate from 80% before Anakinra to 10% after 
Anakinra, based on previous evidences in literature8–21,26, with a power of 90% at a 
confidence level of 95%. Continuous variables, presented as means and standard 
deviations, were compared by non-parametric tests: Mann-Whitney’s test was used for 
independent data and Wilcoxon’s signed-rank test for paired data (pre-post evaluations). 
Categorical variables, presented as counts and percentages, were compared using the 
chi-square test with Yates’ correction or Fisher’s exact test as appropriate. The survival 
probability and the freedom from adverse events were evaluated with the Kaplan-Meier 
curves, compared by the Mantel-Cox test. All analyses were performed using the SPSS 
version 18.0 (SPSS, Inc., Chicago, Illinois) and a two-sided significance level of <0.05 was 




A total of 224 RRP patients were included in the present registry, in a total of 14 
centers across 6 different countries. The inclusion rate ranged from 1 to 53 patients, based 
on center volume and local practice (see appendix A). Each center enrolled consecutive 
patients in order to reproduce real-life practice and avoid any selection bias. Baseline 
population characteristics are reported in Table 1. 




Patients included in the registry had a mean age of 46 years old (range, 18-84), 140 
(63%) were of female gender. Pericardial disease duration before the enrollment was 
27±32 months, with 5.3±3.7 previous recurrences (range, 2-27), 2.5±2.8 ED admissions 
(range, 0-15) and 2.2±2.1 hospitalizations (range, 0-12). Recurrence rate before starting 
anakinra was 2.33 flares-patient/year, implying a mean of 1 recurrence every 157 days. 
ED admission rate was 1.08 admissions-patient/year while hospitalization rate was 0.99 
hospitalizations-patient/year before starting anakinra. 
All patients were diagnosed with recurrent pericarditis at the time of enrollment. Most 
patients had an idiopathic etiology (167 patients, 75%), CRP elevation (203 patients, 91%) 
and echocardiographic evidence of pericardial effusion (196 patients, 88%). At the time of 
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enrollment, medical treatment included NSAIDs in 170 patients (76%), colchicine in 198 





Pericarditis recurrences after anakinra 
During a follow-up of 3889 months-patient, one or more pericarditis recurrences were 
observed in 78 patients, with a flare-free time of 12±11 months (range, 0.33-48). Multiple 
recurrences were observed in 27 patients. 
After anakinra initiation, a mean of 0.6±1 recurrences (range, 0-7) were observed. 
Recurrence rate after starting anakinra was 0.39 flares-patient/year, implying a mean of 1 
recurrence every 939 days. Overall, an 83% reduction in recurrence rate was observed 
(p<0.001, rate ratio 0.17, 95% CI 0.14 - 0.20), equivalent to 1.94 less flares-patient/year. 
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At 36 months after anakinra initiation, 72% patients experienced none or at most one 
recurrence: respectively 43% patients were in stable remission without any recurrence 
while 29% patients had a single recurrence over a period of 36 months. The remaining 
29% patients had two or more recurrences during the follow-up (range, 2-7). 
 
ED admissions and hospitalizations after anakinra 
During the follow-up a mean of 0.1±0.5 ED admissions (range, 0-4) and 0.2±0.5 
hospitalizations (range, 0-2) were observed, corresponding to respectively 0.10 ED 
admissions-patient/year and 0.14 hospitalizations-patient/year. Compared to the period 
prior to treatment initiation, it was observed a reduction of 91% for ED admissions 
(p<0.001, rate ratio 0.09, 95% CI 0.06 - 0.13) and 86% for hospitalizations (p<0.001, rate 
ratio 0.14, 95% CI 0.11 - 0.19). 
Twenty patients (8.9%) were admitted to cardiac surgery department and underwent 
pericardiectomy after 10±9 months (range, 1.8-38). These patients discontinued treatment 
with anakinra and terminated the follow-up observation by the time of intervention. 
 
Corticosteroid-dependence after anakinra 
Although all enrolled patients were corticosteroid-dependent, at the exact time of 
enrollment 180 patients (80%) were still on active treatment with steroids. After the 
initiation of anakinra treatment, during the follow up only 61 patients (27%) remained on 
active treatment. In all other patients, steroids could be tapered and discontinued without 
any symptom recurrence. 
After starting anakinra, colchicine was continued in most patients. During the follow-up, 
131 patients (58%) were still on active treatment. NSAIDs were withdrawn in most patients 
and only 54 (24%) were still on active treatment during the follow-up. 




Adverse events were observed in 99 patients (44%), as described in Table 2. 
Most frequent AE was a transient skin reaction at injection site (associated with 
erythema, itchy wheals, ecchymosis, pain), which occurred in 86 patients (38%), 13±16 
days after the beginning of treatment. Three patients (1.3%) required permanent drug 
discontinuation because of intolerable symptoms. 
Arthralgias and myalgias were reported by 13 patients (6%) during the treatment. One 
of these patients (0.4%) needed drug withdrawal. 
Seven patients (3%) had a mild transient transaminases elevation (SGOT, SGPT) 
without any signs or symptoms of hepatic failure.  
Infections were observed in 6 patients (3%) during the follow-up: two respiratory 
infections (bronchopneumonia), four skin and soft-tissue infections (skin abscess, 
cryptococcus neoformans necrotizing cellulitis, lymphocele infection, pelvic cyst infection). 
In half cases anakinra was temporarily suspended and only one patient was permanently 
discontinued (patient with skin abscess). In all patients infections were successfully 
resolved with proper treatment. 
A transient neutropenia was observed in 3 patients (1%), not associated with clinical 
events, with subsequent resolution.  
Some other AE, with questionable association with anakinra treatment, were reported 
by single patients as follows: hypereosinophilia, mild serotine fever, hot flashes and 
sweating, perforated diverticulitis, optic neuritis. 
Overall, 7 patients (3%) discontinued permanently anakinra after an AE, as 
aforementioned. Among these, one patient discontinued the drug because of multiple AE 
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Treatment duration and tapering 
Patients were treated with full-dose anakinra for a median duration of 6 months (IQR 
3-12), followed by a tapering period with a median duration of 3 months (IQR 0-6). 
Tapering modality varied across patients and centers, as described in Table 3. 
Almost half patients (44%) suspended gradually the active drug, while other 17% 
patients abruptly interrupted the treatment. 
 
Version 1- Jan 22, 2019 
 14 
 
Patients who received a full-dose treatment for more than 3 months had a lower 
recurrence rate at 36 months (54% vs. 72%, p=0.029), as shown in Kaplan-Meier curves 
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All patients who abruptly discontinued anakinra had one or more recurrences within 36 
months. Among other patients who suspended gradually anakinra, those with a short 
tapering (3 months or less) had a higher 36-months recurrence rate compared with those 
with a long tapering (more than 3 months) (74% vs. 21%, p<0.001) as shown in Kaplan-





Baseline and drug management factors associated with pericarditis recurrence 
As to further investigate the association of baseline factors and drug management 
factors with pericarditis recurrence, an univariate analysis was carried out and the 
following variables showed a significant correlation with the risk of recurrence during 
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follow-up: autoimmune etiology, pericardial effusion at anakinra start, discontinuation of 
anakinra treatment, full-dose treatment longer than 3 months, tapering duration longer 
than 3 months. Such factors were then evaluated with a Cox-regression analysis to 
appraise the independent weight of each factor on the risk of recurrence over time, as 
shown in Table 4.  
A longer duration of full-dose treatment (p=0.009, RR=0.41) and a longer duration of 





This is the first international registry on the use of anakinra in patients with 
corticosteroid-dependent and colchicine-resistant refractory recurrent pericarditis. Its 
clinical management is challenging since patients do not respond to colchicine and are 
corticosteroid-dependent, being unable to suspend them without incurring in recurrences. 
According to 2015 guidelines of the European Society of Cardiology7, anakinra may be 
considered as a third-line option in this context. This recommendation has a low level of 
evidence (C, based on case series and expert opinion) in the absence of strong evidence 
in literature (single case reports, some case series and a recently published trial on 21 
patients not available at the time of 2015 ESC guidelines publication26).  
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Two hundred twenty-four patients were included in this study, with a mean pericardial 
disease duration of 27 months and a mean of 5.3 previous recurrences before the starting 
of anakinra 100mg/day sc.  
The main findings of this registry are that anakinra dramatically decreased pericarditis 
recurrence rate (6-fold reduction, from 2.33 flares-patient/year to 0.39 flares-patient/year), 
ED admissions (11-fold reduction, from 1.08 admissions-patient/year to 0.10 admissions-
patient/year), hospitalizations (7-fold reduction, from 0.99 hospitalizations-patient/year to 
0.13 hospitalizations-patient/year) and corticosteroids dependence (before anakinra 80% 
patients were on active treatment, after 27%).  
Anakinra allowed a reduction in pericarditis burden from a mean of one recurrence 
every 157 days to a mean of one every 939 days. At 36 months after anakinra initiation, 
43% patients were in stable remission without any recurrence while 29% other patients 
had only a single recurrence over the entire period. Compared with the only available 
trial26 on 21 patients (AIRTRIP), the efficacy of anakinra is confirmed also in a real life 
population. Indeed, the proportion of patients with stable remission at 8 months was 82% 
in the AIRTRIP and 82% in this study, with only a slight difference in the incidence rate: 
0.11 flares-patient/year in the AIRTRIP and 0.39 flares-patient/year in this real-world 
registry.  
Treatment with anakinra allowed corticosteroids withdrawal in most patients, with only 
27% patients still on corticosteroid treatment during the follow-up. This is important since 
corticosteroids side effects may be severe and affect up to 25% of chronically treated 
patients4.  
Chronic inflammation underlying recurrent pericarditis is probably determined by an 
amplified and self-sustained auto-inflammatory or auto-immune response following 
different exogenous or endogenous triggers5,6. Anakinra is a recombinant IL-1 receptor 
antagonist which inhibits IL-1 action, recently promising in the setting of recurrent 
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pericarditis but already used since more than 15 years for the treatment of rheumatoid 
arthritis and various monogenic and polygenic systemic autoinflammatory disease (such 
as TRAPS and FMF)5. The results of our study further confirm the critical role of IL-1 in 
RRP pathogenesis. 
The safety profile of anakinra is reassuring in a real-world population: no life-
threatening AE were recorded and most of them were mild, predominantly related to 
transient local skin reactions, with an incidence (38%) in line with previous studies 
(44%)29. Skin reactions can be treated with oral antihistamines and topical corticosteroids. 
Furthermore, their occurrence can be limited by warming anakinra syringe to room 
temperature before use, along with application of a cold pack to the area of injection for 
some minutes before and after drug administration30. Among other AE we observed: 
arthralgias and myalgias (6%), transaminases elevation (3%), neutropenia (1%). These 
two latter AE had been previously reported in literature with an incidence of respectively 
14%26 and 1.5%31. Significant infections during treatment with IL-1 antagonists are rare: in 
a review of clinical trials32, they occurred in 1.7% patients, mostly respiratory and soft-
tissue infections. In the present real-world registry, we observed 6 infections (3%), 
predominantly involving the respiratory system and soft-tissues, which were all resolved 
with proper treatment. Seven patients (3%) required permanent anakinra discontinuation 
because of AE. 
A recent review by Lazaros et al.5, investigating current evidence and future 
challenges on anakinra treatment for RRP, underlined that the main unresolved issues in 
this area were the duration of initial treatment and the tapering protocol. To address this 
purpose, this registry demonstrated that both a full-dose treatment duration of at least 3 
months is associated with a lower risk (RR=0.41) of 36-month recurrence rate (54%) as 
long as a more cautious tapering of at least 3 months, which is associated with a lower risk 
(RR=0.19) of 36-month recurrence (21%). The tapering scheme associated with the lowest 
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risk of recurrence is to reduce to 1 dose every other day (for at least 3 months), then 
further reduce slowly to half dose every other day, etc.  
The main limitation of this study is its observational design. Larger randomized and 
controlled trials should be done in the future to confirm these findings in comparison with a 
placebo-control group. However, the main strength is that provides encouraging data 
regarding the efficacy and safety of anakinra also in a real-world population. 
In conclusion, anakinra is a safe and efficacious option for corticosteroid-dependent and 
colchicine-resistant refractory recurrent pericarditis despite optimal anti-inflammatory 
therapy (NSAIDs, colchicine and corticosteroids). A full-dose treatment duration of at least 
3 months followed by a tapering period of at least 3 months were the therapeutic schemes 
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